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Abstract
Background: Meningococcal meningitis is a major cause of disease worldwide, with frequent epidemics
particularly affecting an area of sub-Saharan Africa known as the “meningitis belt”. Neisseria meningitidis group A
(MenA) is responsible for major epidemics in Africa. Recently W-135 has emerged as an important pathogen.
Currently, the strategy for control of such outbreaks is emergency use of meningococcal (MC) polysaccharide
vaccines, but these have a limited ability to induce herd immunity and elicit an adequate immune response in
infant and young children. In recent times initiatives have been taken to introduce meningococcal conjugate
vaccine in these African countries. Currently there are two different types of MC conjugate vaccines at late stages
of development covering serogroup A and W-135: a multivalent MC conjugate vaccine against serogroup A,C,Y
and W-135; and a monovalent conjugate vaccine against serogroup A. We aimed to perform a structured
assessment of these emerging meningococcal vaccines as a means of reducing global meningococal disease
burden among children under 5 years of age.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was
done in two stages. In the first stage we systematically reviewed the literature related to emerging MC vaccines
relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts
(leading basic scientists, international public health researchers, international policy makers and representatives of
pharmaceutical companies). They answered questions from CHNRI framework and their “collective optimism”
towards each criterion was documented on a scale from 0 to 100%.
Results: For MenA conjugate vaccine the experts showed very high level of optimism (~90% or more) for 7 out of
the 12 criteria. The experts felt that the likelihood of efficacy on meningitis was very high (~90%). Deliverability,
acceptability to health workers, end users and the effect on equity were all seen as highly likely (~90%). In terms of
the maximum potential impact on meningitis disease burden, the median potential effectiveness of the vaccines in
reduction of overall meningitis mortality was estimated to be 20%; (interquartile range 20-40% and min. 8%, max
50 %). For the multivalent meningococcal vaccines the experts had similar optimism for most of the 12 CHNRI
criteria with slightly lower optimism in answerability and low development cost criteria. The main concern was
expressed over the cost of product, its affordability and cost of implementation.
Conclusions: With increasing recognition of the burden of meningococcal meningitis, especially during epidemics
in Africa, it is vitally important that strategies are taken to reduce the morbidity and mortality attributable to this
disease. Improved MC vaccines are a promising investment that could substantially contribute to reduction of child
meningitis mortality world-wide.
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Meningococcal disease continues to be a major cause of
childhood morbidity and mortality worldwide. The
annual number of cases is conservatively estimated to
be 1.2 million with at least 135,000 related deaths [1].
The majority of the deaths occur in developing coun-
tries. The area most significantly affected stretches
across sub-Saharan Africa and has become known as
the “meningitis belt” (Figure 1). Cyclic epidemics occur
in this region every 5-12 years and exhibit a marked sea-
sonality [2,3].
The incidence rate in epidemic years can reach 1000
per 100,000 population [4]. It has been estimated that
since 1988 there have been over one million cases of
meningitis in Africa [5]. The largest epidemic occurred
in 1996–1997 across Africa, causing over 250,000 cases
and 25,000 deaths. In recent years the reported number
of meningitis cases has been increasing, with 41,526
cases in 2006, 45,997 in 2007, and 88,199 cases in 2009.
This may reflect a new epidemic wave in sub-Saharan
Africa [5].
The main etiological agents for bacterial meningitis
are Haemophilus influenzae, Streptococcus pneumoniae,
and Neisseria meningitidis [6]. Recently, the incidence of
Haemophilus influenzae meningitis has declined follow-
ing the introduction of the Haemophilus influenzae type
b (Hib) conjugate vaccine [7,8]. Neisseria meningitidis is
now estimated to account for 60-65% of all cases [2].
There are approximately 1.2 million cases of invasive
meningococcal disease leading to 135,000 related deaths
annually, according to the WHO [9]. In non-epidemic
situations, pneumococcus is probably as common across
all age groups as Neisseria meningitidis and causes three
to five times more mortality. During major Neisseria
meningitidis epidemics the proportion due to Neisseria
meningitidis (and particularly MnA) is probably closer
to 90%. Six capsular groups (A,B,C, W-135, X and Y)
are associated with all invasive disease, groups B and C
causing most cases in industrialised countries. Neisseria
meningitidis serogroup A (MenA) was found to be the
most frequent identified pathogen during epidemics in
Africa [6,9]. However, in the years 2000 and 2001, ser-
ogroup W135 caused a major outbreaks during the
annual Hajj pilgrimage in Saudi Arabia [10,11] and was
also subsequently isolated from 80% of cerebrospinal
fluid (CSF) samples in the 2002 epidemic in Burkina
Faso and was also noted in other African countries [12].
Recently, groups X (mainly in Africa) and group Y (in
the United States and otherc o u n t r i e s )h a v ea l s o
emerged as important disease-causing isolates [9].
Different strategies have been implemented to stem
the effects of the epidemics and their associated disease
burden. Currently an emergency strategy of mass vacci-
nation with MC polysaccharide vaccine following early
detection of cases is instituted in the epidemic area [3].
However, this is a short-term solution and the strategy
relies on timely surveillance and rapid response, both of
which can be difficult to achieve in less-developed coun-
tries. Delays in vaccination can be associated with
increased morbidity and mortality [13]. The polysac-
charide vaccine against serogroup A does not prevent
acquisition of nasopharyngeal carriage or confer herd
 meningitis belt  epidemic zones  sporadic cases only 
Figure 1 Demography of meningococcal meningitis (Source http://en.wikipedia.org/wiki/File:Meningitis-Epedemics-World-Map.png).
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Page 2 of 14immunity [14] and the vaccine response with repeated
administration over time (for example with immuniza-
tions of at-risk populations during repeated epidemics)
is uncertain [15]. The immunogenic response to the vac-
cine is diminished in infant and young children under
the age of two years [16,17]. This is an important limita-
tion given the epidemiology of meningococcal disease.
These shortcomings may be overcome by the develop-
ment of MC conjugate vaccines (named after the linking
of the MC polysaccharide antigen to immunogenic car-
rier proteins) if optimally realized. However, some of
these limitations are also true for the MC conjugate vac-
cines. For example the immunogenicity of a quadriva-
lent (A, C, W135, and Y) vaccine conjugated to
diphtheria toxoid in infants is poor [9].
We aimed to assess the potential of the MC conjugate
vaccines to reduce global under-5 meningitis mortality
through the use of the CHNRI priority setting
methodology.
Methods
We used a modified Child Health and Nutrition
Research Initiative (CHNRI) methodology for setting
priorities in health research investments. The methodol-
ogy has been described in great detail [18-22] and
implemented in a variety of settings [23-28].
CHNRI exercise – stage I: Identification and selection of
studies
We applied the CHNRI method to estimate their poten-
tial impact of the emerging MC conjugate vaccines
against two major serogroups of Neisseria meningitidis
(A and W-135). We conducted a systematic literature
review using the following 12 criteria: answerability, cost
of development, cost of product, cost of implementation,
efficacy and effectiveness, deliverability, affordability,
sustainability, maximum potential impact on disease
burden reduction, acceptance to health workers, accep-
tance to end users and equity (Figure 2). Details about
the search strategies are presented in Additional file 1.
The search was limited to Ovid MEDLINE (1999 to July
2009), EMBASE (1999 to July 2009), Web of Science
(1999 to July 2009), Cochrane central register for con-
trolled trials and a grey literature database (SIGLE). In
order to ensure completeness, we also conducted hand
searching of online journals, scanned the reference list
of identified citations, and perused literature available
on the websites of pharmaceutical companies and inter-
national agencies (GAVI and WHO).
Eligible studies were selected according to the pre-
determined inclusion criteria. In particular, included stu-
dies investigated the answerability, effectiveness, deliver-
ability, disease burden reduction or equity of vaccines or
immunisation programs related to meningococcal conju-
gate or combination vaccines. Studies not eligible for
inclusion were studies: (i) non-English language studies
and (ii) developed world vaccine trials where developing
world results for the same vaccine exist.
CHNRI exercise – stage II: An expert opinion exercise
We shared the initial review of the literature with 20
experts. The list of chosen experts included five leading
basic scientists, five international public health research-
ers, five international policy makers and five representa-
tives of the pharmaceutical companies. The 20 experts
were chosen based on their excellent track record in
childhood disease research, or prominent leadership
roles in their organization related to this subject. We
initially offered participation to the 20 experts with the
greatest impact of publications in their area of expertise
over the past 5 years (for basic researchers and interna-
tional public health researchers), or for being affiliated
to the largest pharmaceutical company in terms of vac-
cination programme or international agency in terms of
their annual budget. For those who declined or who
could adjust their schedules to participate (4 experts or
20%) replacements were found using the same criteria.
The policy makers and industry representatives accepted
our invitation on the condition of anonymity, due to
sensitive nature of their involvement in such exercises.
The experts met during September 7-13, 2009 in
Dubrovnik, Croatia, to conduct the 2
nd stage of CHNRI
expert opinion exercise. The process of second-stage
CHNRI is shown in Figure 3. All invited experts dis-
cussed the evidence provided in CHNRI stage I, and
then answered questions from CHNRI framework see
Additional file 2. Their answers could have been “Yes”
(1 point), “No” (0 points), “Neither Yes nor No” (0.5
points) or “Don’tk n o w ” (blank). Their “collective opti-
mism” towards each criterion was documented on a
scale from 0 to 100%. The interpretation of this metric
for each criterion is simple: it is calculated as the num-
ber of points that each evaluated emerging intervention
received from 20 experts (based on their responses to
questions from CHNRI framework), divided by the max-
imum possible number of points (i.e., if all the answers
from all the experts to all the questions were “Yes”).
Results
After initial screening, sixty studies were finally included
in the review. Thirty one of them were considered for
assessing the answerability and effectiveness of monova-
lent and quadrivalent meningococcal vaccines covering
M Cs e r o g r o u pAa n dW - 1 3 5a n df o u r t e e ns t u d i e sw e r e
considered to assess the deliverability, equity and reduc-
tion in global burden of disease from meningitis.
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The conjugate vaccine boosts immunogenicity by trans-
forming the vaccine from T-cell independent to T-cell
dependant, thus allowing for priming of immunological
memory and increasing immunogenicity in infants [3].
Conjugate vaccine technology has made significant
advances in the past two decades [15] Hib conjugate
vaccine was first licensed in 1987 followed by MenC
conjugate in 1999 and pneumococcal conjugate (PCV7)
vaccine in 2000 [29]. These conjugate vaccines were
f o u n dt ob es a f ea n di m m u n o g e n i ci ni n f a n t s .T h ee f f i -
cacy of these conjugate vaccines has demonstrated that
the principle that the immunogenicity of bacterial cell
surface polysaccharides can be improved by conjugating
Figure 2 A summary of Stage I of the CHNRI process of an evaluation of emerging intervention (a systematic review of the key CHNRI criteria).
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emerging MC conjugate vaccines is building on an
established technology which has been shown to be
successful.
The currently available MenC conjugate vaccines were
first introduced in the UK in November 1999. Two differ-
ent conjugated MenC conjugate vaccines were developed
using CRM197 and one with tetanus toxoid as the carrier
proteins [2]. These vaccines were licensed on the basis of
immunogenicity and safety data but without a formal effi-
cacy study. Studies reviewing the impact of MenC
conjugate vaccines reported short term efficacy of 97% for
teenagers and 92% for toddlers in England [30]. One year
following introduction of these vaccines a 66% decrease in
the prevalence of nasopharyngeal carriage of serogroup C
meningococcal in adolescents [31] and 67% reduction in
the attack rate in the unvaccinated adolescent population
conferring a high level of herd immunity [32]. This experi-
ence therefore suggests that the development of further
MC conjugate vaccines against other serogroups should,
in principle, be a realistic possibility and could provide
better protection against meningitis.
Figure 3 A summary of Stage II of the CHNRI process of an evaluation of emerging intervention (an expert opinion exercise using the CHNRI
criteria).
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Page 5 of 14The panel was very optimistic (score over 85%) about
the ability of a monovalent conjugate vaccine against
MenA to satisfy the criteria of answerability (Figure 4)
while they were somewhat less optimistic (score about
75%) in the case of multivalent MC conjugate vaccines
(Figure 5).
Efficacy and effectiveness
Monovalent Conjugate Vaccine against Serogroup A
A serogroup A meningococcal conjugate vaccine using
tetanus toxoid as a carrier protein (PsA-TT conjugate
vaccine) (MenAfrivax) has been developed at the Serum
Institute of India Ltd. (SIIL) using a new licensed conju-
gation technique from the Center for Biologics Evalua-
tion and Research/Food and Drug Administration
(CBER/FDA, MD, USA) [33]. The vaccine demonstrated
higher serum bactericidal antibody (SBA) than the PS-
only vaccine in animal studies [34]. The first Phase I
clinical trial was carried out in India among 18-35 year
old healthy volunteers and results of the study showed
PsA-TT to be safe, immunogenic and able to demon-
strate long term functional antibody titers in adults (Fig-
ure 6) [35].
A Phase II clinical trial in Mali and Gambia evaluate
t h ei m m u n o g e n i c i t ya n ds a f e t yo fas i n g l ei n j e c t i o no f
PsA-TT vaccine in young children compared to a
licensed meningococcal ACWY polysaccharide vaccine
(PsACWY) and a licensed Hib conjugate vaccine (Figure
6). The preliminary results showed 96% of the subjects
in PsA-TT group had a four-fold increase in rSBA titer
from week 0 to 4 as compared to 64% in the ACWY PS
group and 36% in Hib group [36]. A Phase II/III clinical
trial with 909 subjects of 2-29 year olds was carried out
in Mali, Senegal, and the Gambia comparing the immu-
nogenicity and long-term persistence of antibodies of a
single dose of the PsA-TT vaccine with that of
PsACWY. The preliminary findings were presented at
International Pathogenic Neisseria Conference in 2008
which concluded that the PsA-TT vaccine is safe and
consistently induced higher immune responses with
respect to the licensed tetravalent polysaccharide vac-
cine. The immune response as measured by the MenA
IgG ELISA concentrations ≥ 2 μg/mL was 100% (CI 99-
100) in PsA-TT group and 88% (CI84-92) in the
PsACWY group [37,38]. Preliminary results of similar
Phase 2/3 study in India in healthy children of 2–10
years of age showed that the vaccine was safe and highly
immunogenic [39]. Two Phase 3 clinical trials are cur-
rently being carried out in India and Mali to evaluate
t h es a f e t ya n di m m u n o g e n i c i t yo fas i n g l ed o s eo ft h e
PsA-TT vaccine [40].
Based on these, the experts were very optimistic (score
over 85%) regarding the likelihood of efficacy of the mono-
valent conjugate vaccine against meningitis (Figure 4).
Multivalent Vaccines against Serogroup A and W-135
The two currently available meningococcal conjugate
vaccines in developed world that target both MenA and
MenW-135 along with serogroup C and Y are Menactra
and Menveo.
Menactra (Meningococcal ACWY-diphtheria vaccine;
MenACYW-D; Sanofi Pasteur) is a quadrivalent menin-
gococcal protein–polysaccharide conjugate vaccine
licensed for use in the United States for routine vaccina-
tion of 11–12 years old and for increased risk of invasive
meningococcal disease (IMD) of 2–55 years old for both
Canada and USA.
Menveo is a quadrivalent glycoconjugate vaccine,
(MenACWY-CRM, Novartis Vaccines), formulated from
oligosaccharides of MenA (10 g) and of Men C, W-135
and Y (5 g of each) and covalently linked to the
diphtheria mutant toxin carrier protein, CRM197. In
early 2010, the vaccine received approval from the Fed-
eral Drug Administration and European Medicines
Agency for use among teenagers and adults.
These vaccines offer protection against four of the five
most common meningococcal serogroups: A, C, Y and
W-135.
A randomized controlled trial was conducted among
11-18 years old comparing the immunogenecity of
Menactra with Menomune (PSV-4; A/C/Y/W-135;
Sanofi Pasteur Inc), a licensed tetravalent polysaccharide
vaccine (Figure 6). The findings of the study showed a
high percentage of subjects with fourfold or greater rise
in serum bactericidal activity for all four antigens (the
seropositivity was measured by Serum Bactericidal Assay
with baby rabbit complement (rSBA)). The respective
seroresponse rate in Menactra and Menomune for
MenA, MenC, MenY and MenW-135 are presented in
Figure 7[41]. Another randomized controlled trial con-
ducted among persons aged 18–55 years compared
immunogenecity of Menactra and that of Menomune at
28 days after vaccination showed similar results (Figure
7) [42]. A study in children aged 2–10 also found signif-
icantly higher seroresponse as measured by SBA activity
in the Menactra group [43].
A similar phase III randomized controlled trial was
carried out to compare the safety and immunogenicity
of Menveo with that of Menactra. The results of the
trial were published separately for the 11-to 18-year
old and 19- to 55- year old groups [44,45]. The sero-
respnose rates of Menveo and Menactra as measured
by hSBA titre>= 1:8 at 1 month following the last dose
for both age groups are presented in Figure 7. To eval-
uate immunogenicity and reactogenicity of Menveo in
healthy infants, a study was conducted in Canada and
the UK. It concluded that Menveo is immunogenic
and well tolerated in infancy and could provide broad
protection against meningococcal disease in this age
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Page 6 of 14group [46]. A new Quadrivalent Meningococcal (A, C,
Y and W-135) Tetanus Protein Conjugate Vaccine
(TetraMen-T) is in late stages of development from
Sanofi Aventis (http://clinicaltrials.gov/ct2/show/
NCT01049035) and a quadrivalent Meningococcal (A,
C, Y, W-TT) Protein Conjugate Vaccine from GSK
nearing licensure [47-49].
A novel heptavalent vaccine targeting Neisseria
meningitidis serogroups A and C along with
diphtheria, tetanus, whole cell pertussis-hepatitis B
Mn A conjugate vaccine
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conjugate vaccines.
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Page 7 of 14virus and Hib (DTPw-HBV/Hib-MenAC) was devel-
oped and was found to be safe and efficacious at gen-
erating immunological memory, particularly in infants
in initial Phase I/II studies (Figure 6). A dose-ranging
trial in the Philippines in 524 healthy infants showed
that the DTPw-HBV/Hib-MenAC vaccine produced
antibody responses comparable to the non-combina-
tion vaccines [50]. Another Phase II study on DTPw-
HBV/Hib-MenAC in Ghana demonstrated adequate
immunogenecity in infants [51]. However, currently
there are no plans to take this vaccine forward for
registration [52].
Multivalent Mn vaccine
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ducted to evaluate the effectiveness of these multivalent
vaccines in developing world settings. Although immu-
nogenicity studies usually can predict short-term effec-
tiveness, the understanding of long-term protection
needs well designed effectiveness trials. Moreover
studies should be carried out to gather knowledge on
link between immunogenicity and impact on nasophar-
yngeal carriage and herd immunity in the epidemic
prone areas.
Based on the available information, the expert group
w a sv e r yo p t i m i s t i c( s c o r eo v e r8 5 % )r e g a r d i n gt h e
Figure 6 The current status of the research into MenA conjugate vaccines, multivalent Men conjugate vaccines and DTPw-HBV/Hib-MenAC
vaccines as of September 2009 (see Additional file3 for details about the clinical trials phases; The DTPw-HBV/Hib-MenAC has now been
discontinued).
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Page 9 of 14likelihood of efficacy of the multivalent conjugate MC
vaccines against meningitis (Figure 5).
Cost, affordability, deliverability and sustainability
The ongoing MenA clinical trials are currently evaluat-
ing the efficacy of different schedules of vaccination in
infants. The Meningitis Vaccine Project (MVP) proposes
delivery of the MenA conjugate vaccine in a two dose
schedule, at 14 weeks and 9 months, or as a single dose
a t9m o n t h s[ 2 ] .Ac a t c h - u pf r o ma g e1t o2 9y e a r si s
planned for each meningitis belt country. This permits
incorporation of the vaccine into existing EPI schedules,
since it will be given concurrently with the final DPT
dose (DTP3) at 14 weeks and with the measles vaccine
at 9 months [53]. This should act to promote high cov-
erage of the MenA vaccine without the need to commit
very substantial further resources for promotion and
delivery of a new immunisation programme. In 2006,
the average uptake of the DTP3 vaccine across the Afri-
can region was 73%, with similar rates of coverage for
the measles vaccine [54]. However, this masks pro-
nounced disparities between countries, in the “meningi-
tis belt”. For example, Niger achieved <40% coverage for
DTP3 while rates in Burkina Faso and the Gambia were
>90%, which suggests that approaches to vaccine
delivery must be modified in areas where current strate-
gies have low uptake. Such countries may benefit from
the implementation of periodic regional campaigns to
boost immunisation coverage [54].
Provision of viable vaccines relies on appropriate sto-
rage and transport and a functioning “cold-chain”.C u r -
rently, there is a significant wastage of vaccines in
developing countries due to inadequate funding, poor
equipment and lack of training of health-care workers
[55]. Storage is an important factor to address as the
MenA Ps, from which the conjugate is derived has been
shown to be the least stable meningococcal Ps [56] and
any deviation from the recommended 2-8°C storage
temperature [55] could render the vaccine unusable.
This is also applies to the multivalent conjugate
vaccines.
The greatest barrier to uptake of vaccines by develop-
ing countries is cost [57]. The MVP was been granted
$70 million by The Gates Foundation [57] and $29.5
million from The Global Alliance for Vaccines and
Immunisation (GAVI) [58], which should allow Men A
conjugate vaccine to be provided at $0.40 a dose, in
agreement with the manufacturer, the Serum Institute
of India Limited [3]. Currently the MVP aims to provide
the Men A conjugate vaccine at a lower cost through
Comparison of immunogenecity of Menactra with Menomune 
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Figure 7 Seroresponse rate in Menactra and Menomune for MenA, MenC, MenY and MenW-135 ((1) Keyserling, H., et al: Safety, immunogenicity,
and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in
healthy adolescents. Arch Pediatr Adolesc Med, 2005, 159: 907-13; (2) Bilukha, O.O. and N. Rosenstein: Prevention and control of meningococcal
disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2005, 54: 1-21; (3) Jackson, L. A.,
et al: Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY
conjugate vaccine in adolescents. Clin Infect Dis 2009, 49: e1-10; (4) Reisinger, K. S., et al : Quadrivalent meningococcal vaccination of adults:
phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009,
16: 1810-1815.).
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Page 10 of 14push financing. MenAfriVac™ has received WHO pre-
qualification (which guarantees that individual vaccines
meet international standards of quality, safety, and effi-
cacy). The producer, Serum Institute of India Ltd, has
received marketing authorization for export and use of
MenAfriVac™ in Africa and mass introduction will start
in late 2010 in Mali, Burkina Faso and Niger with back-
ing from Global Alliance for Vaccines and Immuniza-
tion (GAVI) and WHO. Given the emergence of the
importance of the W-135 and X serogroups in Africa,
the program should be flexible enough to introduce
multivalent conjugate vaccines targeting A, W-135 and
X serotypes if necessary.
The panel was highly optimistic (score around 90%)
that a monovalent conjugate vaccine could be developed
at a low cost (Figure 4), while they were only moderately
optimistic (score about 70%) in case of multivalent vac-
cines (Figure 5). They were however optimistic that
once introduced with support from donor agencies like
GAVI Alliance the vaccine delivery was sustainable. The
main concern related to both vaccines was expressed
over the cost of product, its affordability and cost of
implementation (Figures 4 and 5).
Burden of disease reduction
In 2009, 88,199 cases of suspected meningococcal dis-
ease were reported in “meningitis belt” countries, result-
ing in 5,352 deaths. The worst hit areas were Nigeria
and Niger which combined accounted for 69,577 cases
and 3,046 fatalities. From 2003-2007, 87.8% of epidemic
cases were attributable to serogroup A and 10% to
W135 [59]. Reactive mass vaccination of epidemic dis-
tricts can prevent up to 70% of cases, if the vaccine
administration happens on time [35]. If MenA conjugate
vaccine can reproduce the effect of the MenC conjugate
vaccine, which prompted a 90% decrease in cases and
70% reduction in rates of carriage in UK [6], then an
even greater reduction in the number of cases can be
expected in Africa. However, this will be determined by
the ability to efficiently deliver the vaccine and obtain
maximum coverage. The effect of a quadrivalent vaccine
on disease reduction is dependant on the uptake of such
a vaccine in the MVP program as well as on virulence/
carriage of the organism, levels of antibodies needed to
eliminate carriage, duration of protection, and other fac-
tors. There have been suggestions that the inclusion of
other serogroups into vaccination programs may lead to
further disease burden reduction in this region [58]. A
recent review of meningococcal carriage during epi-
demics showed W135 and Y causing a greater number
of cases [60]. Combination vaccines with non-EPI dis-
eases may also be beneficial in providing countries with
protection against both meningococcal disease and
those not currently part of that country’s EPI schedule.
This may lead to multi-disease burden reduction as
demonstrated in Ethiopia but given the fact that further
development of combination vaccine DTPw-HBV/Hib-
MenAC has ceased, we may need to wait longer to get
the benefit of such a vaccine [61].
The expert group felt that both the monovalent MC
conjugate vaccines and the multivalent MC conjugate
vaccines had high median potential effectiveness for
reduction of meningitis mortality (20%; interquartile
range 20-40% and min. 8%, max 50%; and 30%; inter-
quartile range 25-40% and min. 9%, max 60%, respec-
tively) (Figures 4 and 5).
Acceptability and equity
A limitation to the improvement of equity is that it
appears inevitable that a health-promotion strategy simi-
lar to those currently employed will reach higher-
income populations prior to the underprivileged, unless
a novel method of introduction is found [62]. This effect
is particularly pronounced in low and middle income
countries in Asia and Africa, where greater inequities
exist [62]. As herd immunity is dependant on high levels
of coverage [2], it is vital that immunizations are deliv-
ered to the poorest areas which are most affected by
disease. The MVP financing strategy for MenA [3] may
allow more periodic immunization campaigns, which
were shown to be effective in Africa [54]. More money
must be spent on strengthening delivery capacity in
these countries to ensure equity is improved. However
multivalent vaccine may cause further inequity due to
the high price of that vaccine. Currently a trivalent A/C/
W135 PS polysacharide vaccine costs US$ 1.30 per dose
[3] which means a novel quadrivalent conjugate vaccine
will be more expensive and be out of reach for the
majority of the population of African countries. The
decision to develop only a low cost Men A conjugate
vaccine through push financing was based on the expec-
tation that other serogroups especially W-135 will not
cause major epidemics. However, in future the control
program may still need to consider the development of
a low cost multivalent vaccine too through push
financing.
The expert group were very optimistic (score over
90%) that both the monovalent and multivalent MC
conjugate vaccines would have a positive impact on
equity, and would be acceptable to both health workers
and end users (Figures 4 and 5).
Discussion
The literature review summarized in this paper presents
available evidence that is useful in considering the rela-
tive priority for investment in emerging MC conjugate
vaccines. The scores of both monovalent MC conjugate
and the multivalent MC conjugate vaccines are
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Page 11 of 14presented against a common set of criteria. These scores
reflect the “collective optimism” of a panel of experts
drawn from varying backgrounds. We have shown that
both the monovalent MC conjugate and multivalent MC
conjugate vaccines are considered to have the potential
to significantly reduce the burden of meningococcal
meningitis in children under the age of 5 years. Coun-
tries in the meningitis belt in general, and the poorer
nations in particular, account for the greatest global
burden of disease due to meningitis. An effective vaccine
distributed worldwide will reduce that burden, and if
delivery is targeted at the poorest areas, the inequity gap
in health will also be reduced.
For MenA MC conjugate vaccine the experts showed a
high level of optimism (~ 90%) for 7 out of the 12 criteria.
The expert group felt that the likelihood of efficacy on
meningitis was very high (~ 90%) and the maximum
potential impact on disease burden was also high. Median
potential effectiveness of the vaccines in reduction of over-
all meningitis mortality was predicted to be 20% (inter-
quartile range 20-40% and min. 8%, max 50%). The MenA
conjugate vaccine scored well on answerability, low devel-
opment cost, likelihood of efficacy against meningitis, deli-
verability, acceptability to health workers and end users,
effect on equity and maximum potential to reduce the
burden of mortality due to meningitis. The multivalent
vaccines scored similarly well on all criteria except answer-
ability and low development cost. The main concern
related to both vaccines was expressed over the cost of
product, its affordability and cost of implementation
Both the monovalent and quadrivalent vaccines have
been shown to have a good safety profile, with high
immunogenicity against MenA and MenW-135 in
young children and adults across Phase II/III trials.
However it is important that well designed controlled
studies are carried out in developing world settings to
provide data on effectiveness. Following demonstration
of the viability of the MenC conjugate vaccine stored at
room temperature, a similar study examining the effect
of storage temperature on the new conjugate vaccines
would be invaluable. This would potentially allow reas-
sessment of deliverability, particularly to communities
with limited cold chain facilities.
The CHNRI methodology was primarily designed to
evaluate existing interventions and competing investment
priorities for health research. Though we used the CHNRI
criteria, we modified it by including systematic review of
available literature and not involving all stakeholders (e.g.
end-users and health workers). The scores included here-
with express the collective opinion of a panel of 20
experts. While there is always an element of uncertainty in
predicting impact of interventions which do not exist and
have no clinical trial data to support them, we feel that the
results would be reproducible with another panel in a
different setting. The literature review also had some lim-
itations. Firstly, the literature search was limited to
selected databases and to articles published in English. In
addition, a variety of key-words yielded results, especially
when searching the domains “deliverability” and “equity”.
A l t h o u g he v e r ye f f o r tw a sm a d et ob ei n c l u s i v e ,s u c ha
broad range increases the chance of missing information
that may be important. Secondly, it was not always possi-
ble to find current literature specific to meningococcal
vaccines. In these circumstances relevant data on other
related vaccines was sought and this may not always be
fully appropriate. Finally, due to marketing patents, retrie-
val of the most recent information on the progress of a
vaccine was generally difficult.
Conclusions
With increasing recognition of the burden of meningo-
coccal meningitis, especially during epidemics in Africa,
it is vitally important that steps are taken to reduce the
morbidity and mortality attributable to this disease. The
strengthening of the surveillance system is important to
support any vaccination program. The increase in inci-
dence of W135 in recent epidemics raises the question
of whether it would be more appropriate to use a multi-
valent vaccine with A and W135 in the “Meningitis
Belt” instead of a monovalent vaccine. New Initiatives
are joining MVP to strengthen the international effort
to eliminate meningococcal epidemics in Africa. A new
international consortium (MenAfriCar) http://www.
menafricar.org/ has started working in Africa and aims
to study patterns of meningococcal carriage and trans-
mission in this region, as well as documenting the
impact of any new MC conjugate vaccine. MenAfriCar
aims to further develop regional capacity for delivery of
immunization programmes. However, success will rely
on concerted and sustained commitment from govern-
ments, charities and health care workers to implement
those vaccination strategies shown by research to be the
most effective and practical/feasible.
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